Inotek Pharmaceuticals Corporation Presents Preclinical Data at ARVO Confirming That INO-8875 Lowers IOP by Increasing Outflow Through the Trabecular Meshwork
Published: May 04, 2010
LEXINGTON, MA--(Marketwire - May 04, 2010) -
Highlights from the ARVO poster titled, "INO-8875, an Adenosine A1 Agonist, Lowers Intraocular Pressure Through the Conventional Outflow Pathway" included:
- INO-8875 in an eye-drop formulation dose-dependently lowered intraocular pressure (IOP) by 20-25% from baseline at 1-2 hours after single doses in normotensive eyes. The IOP-lowering effect of INO-8875 was sustained for 4-6 hours post-dose.
- In human trabecular meshwork cells, INO-8875 rapidly activated the extracellular signal-regulated kinases 1/2 and stimulated the release of matrix metalloproteinase-2 (MMP-2). MMP-2 is thought to be a key player in the processing of extracellular matrix that can accumulate in the trabecular meshwork and impede aqueous humor outflow.
- In isolated, perfused anterior segments of the eye, INO-8875 significantly increased conventional outflow (i.e., outflow through the trabecular meshwork) compared to vehicle.
"These data strongly support INO-8875's potential as a first-in-class product candidate for the treatment of glaucoma," stated Paul G. Howes, Inotek's President and Chief Executive Officer. "INO-8875's elegant mechanism of action utilizes the main pathway used by healthy elderly eyes to maintain normal IOP -- the trabecular meshwork. By delivering the drug directly to the tissue of the trabecular meshwork, INO-8875 is able to increase outflow there, while keeping systemic exposure to the drug low. Based on these findings and the positive results from our single-dose clinical trial of INO-8875 in glaucoma, we plan to initiate our first multiple-dose Phase 2 clinical trial of INO-8875 in glaucoma in mid-2010."
Inotek is a leader in the development of innovative drug candidates that address significant diseases of the eye, with a major focus on glaucoma. Inotek's lead product candidate INO-8875 is a potential first-in-class eye-drop treatment for glaucoma that significantly reduced intraocular pressure (IOP) in glaucoma subjects following single doses applied to the eye in a Phase 1/2 clinical trial. The Company believes INO-8875 will be a breakthrough treatment that can be used alone or combined with other IOP-lowering products because it increases the outflow of aqueous humor through the trabecular meshwork, the primary drainage system used by healthy elderly eyes to maintain normal IOP. The Company is also advancing a broad pipeline of PARP inhibitors and SOD mimetics that alleviate oxidative injury and inflammation, which it believes may address significant unmet medical needs in retinal diseases, such as the dry form of age-related macular degeneration (dry AMD). The Company is located in Lexington, MA. For further information on Inotek, please visit www.inotekcorp.com.
Adam L. Muzikant, Ph.D.
Senior Director, Business Development
MacDougall Biomedical Communications